DiaSorin's 2012, which is closing, goes into the archives with declining sales and margins. Despite the contraction of the results, the Board has proposed to the assembly an increase in dividends compared to last yearfrom 0,46 euro per share in 2011 to 0,50 euro.
Consolidated net revenues, as stated in the note released by the company active in diagnostics, fell by 1,8%, settling at 432 million, while Ebitda fell by 9,7% to 171,7 million. Net income also slips down by -10,1% to 89,5 million. Disappointed analysts, who had expected better results for each of these items.
For 2013, however, DiaSorin's estimates speak of revenue growth between 2 and 4% compared to 2012 and a gross operating margin in line with the previous year.
Meanwhile, in the afternoon, DiaSorin shares fall on the stock market, which lost 4,69% to 28,02 euros per share, placing itself at the bottom of the Ftse Mib.
